Tarsons Products Q1 FY27 Earnings Call — Analysis (NSE: TARSONS)
Tarsons Products delivered Q1FY27 consolidated revenue of ₹110.2 Cr, up 20.7% YoY, with exports rebounding 29% but margins pressured by sharp polymer raw material inflation.
Result quality: poor — Slipped to loss. Management sentiment: neutral.
The take
Q1FY27 Consolidated revenue ₹110.2 Cr ( +20.7% YoY ) .
Results
Consolidated revenue was ₹110.2 Cr, +20.7% YoY; standalone revenue was ₹86.1 Cr, +21% YoY; consolidated EBITDA was ₹26 Cr at a 23.6% margin; standalone gross margin was 67.1%; profit remained moderate on higher depreciation and interest.
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Consolidated revenue | ₹110.2 Cr | +20.7% | yoy · Q1FY27 |
| Standalone revenue | ₹86.1 Cr | +21% | yoy · Q1FY27 |
| Domestic sales growth | 17% | yoy · Q1FY27 | |
| Exports growth | 29% | yoy · Q1FY27 | |
| Standalone gross margin | 67.1% | none · Q1FY27 · of standalone revenue | |
| Standalone EBITDA | ₹24.2 Cr | none · Q1FY27 | |
| Consolidated EBITDA | ₹26 Cr | none · Q1FY27 | |
| Consolidated EBITDA margin | 23.6% | none · Q1FY27 · of consolidated revenue | |
| Consolidated cash profit | ₹25.6 Cr | +18% | yoy · Q1FY27 |
| Standalone cash profit | ₹25.2 Cr | +18% | yoy · Q1FY27 |
| Nerbe constant-currency revenue growth | 6% | yoy · Q1FY27 | |
| Gross debt | ₹380 Cr | point_in_time · Q1FY27 · as of Q1FY27 | |
| Net debt | ₹330-340 Cr | point_in_time · Q1FY27 · as of Q1FY27 |
Guidance
Management guided to at least 15% FY27 standalone growth, with Panchla/Amta contributing 20-25% of standalone revenue in FY28 and new products contributing ₹65-70 Cr in FY28.
Key themes
Capex commercialization, export recovery, input-cost pressure
Operational commentary
- Panchla expansion is in its final commissioning phase: several product lines are already operational, while remaining select lines are in trial runs and expected to be fully commissioned during Q2FY27, with revenue contribution beginning in H2FY27.
- The completed multi-year capex is expected to add ~₹400 Cr incremental revenue at around 0.8x fixed asset turnover, with peak sales potential guided at ₹750-800 Cr.
- Exports from India rebounded 29% YoY, helped by recovering customer inquiries, order conversions, trade fair-led customer additions, and emerging white-label opportunities.
- Nerbe Germany grew ~6% YoY in constant currency; management sees growth runway through cross-selling Tarsons-manufactured products and expanding Nerbe beyond Germany and the EU.
- Domestic demand recovery is visible, with inquiry momentum improving and the market returning toward late single-digit pre-COVID growth; government/institutional demand is estimated at 15-20% of the ₹1,200-1,300 Cr domestic market.
- New product commercialization is progressing: bioprocess containers, media bottles, and roller bottles are already selling, and the full new portfolio is expected to contribute ₹65-70 Cr in FY28.
- A senior sales leadership hire has been onboarded and mid-to-senior sales roles are being added below that position; international sales currently run from India.
- No major new capex is planned beyond completion of existing projects; maintenance capex is expected to remain around ₹20-25 Cr per year, and no government incentives have been taken for Panchla/Amta.
Analyst Q&A
Q. How will Tarsons compete against global peers with stronger balance sheets and larger SKU counts in exports?
Management said Tarsons is a lean company producing high-quality products at reasonable prices and can penetrate segments global branded peers ignore; the bigger near-term issues are war, inflation, tariffs, logistics, and transportation rather than global competition.
Research and educational content only. Not investment advice.